24/7 Market News Snapshot 04 September, 2025 – Bone Biologics Corp Common Stock (NASDAQ:BBLG)
DENVER, Colo., 04 September, 2025 (www.247marketnews.com) – (NASDAQ:BBLG) are discussed in this article.
Bone Biologics Corporation has recently captured significant attention within the financial markets, witnessing a notable pre-market surge where shares are trading at $2.719, reflecting an increase of 31.35% from the previous close of $2.070. This uptick comes alongside impressive trading volume, with about 2.78 million shares changing hands, indicating heightened investor interest and momentum ahead of the market’s opening.
The excitement surrounding Bone Biologics is fueled by its advancements in the development of NB1, a proprietary treatment harnessing recombinant human protein NELL-1 aimed at addressing challenges in spinal fusion. In a recent update to stockholders, CEO Jeffrey Frelick articulated a strategic vision that emphasizes the company’s pioneering role in developing orthobiologic products applicable to spine fusion markets.
Currently, Bone Biologics is conducting a first-in-human pilot study assessing the safety and preliminary effectiveness of NB1 in patients diagnosed with degenerative disc disease. This multicenter clinical trial will evaluate two concentrations of the NB1 bone graft against a traditional autograft control, with an objective to enhance fusion success rates and improve overall patient outcomes. Although patient enrollment has progressed more slowly than anticipated, the company maintains confidence in completing recruitment by the end of the year.
Further solidifying its market position, Bone Biologics has filed a significant U.S. patent application related to the unique compositions of rhNELL-1 polypeptide, ensuring product stability and efficacy. Following a successful public offering that raised $5 million in gross proceeds, the company is positioned to sustain its operational needs through the second quarter of 2026.
As Bone Biologics continues to advance NB1 through critical clinical phases, it not only stands as a leader in orthobiologics innovation but also represents a promising investment opportunity. The ongoing endeavors aim to reshape spinal fusion treatment paradigms and enhance the quality of care for patients, paving the way for improved health outcomes and growth potential within the industry.